Drugs Made In America Acquisition (DMAAR) Common Equity (2024 - 2025)
Drugs Made In America Acquisition (DMAAR) posted Common Equity of -$7.3 million for Q4 2025, down 1293.12% on a QoQ basis from $608822.0 in Q3 2025, and down 2866.77% year-over-year from $262544.0 in Q4 2024.
Drugs Made In America Acquisition (DMAAR) Common Equity (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition's Common Equity history runs 2 years deep, the most recent figure standing at -$7.3 million for Q4 2025.
- Quarterly Common Equity fell 2866.77% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.3 million (down 2866.77% YoY) and the FY2025 annual result came in at -$7.3 million, down 2866.77% from the prior year.
- Common Equity was -$7.3 million for Q4 2025 at Drugs Made In America Acquisition, down from $608822.0 in the prior quarter.
- Across five years, Common Equity topped out at $608822.0 in Q3 2025 and bottomed at -$7.3 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | SIM Acquisition Corp. I | 314.52 Mn | 314.52 Mn | - | -61,075.00 |
| 2 | Thayer Ventures Acquisition | 208.29 Mn | 208.29 Mn | - | -8.18 Mn |
| 3 | Newbury Street II Acquisition | 185.26 Mn | 185.26 Mn | - | -5.50 Mn |
| 4 | Dynamix | 178.78 Mn | 178.78 Mn | - | -27.05 Mn |
| 5 | Hallmark Venture | 103.01 Mn | 102.76 Mn | - | -174,690.00 |
| 6 | Voyager Acquisition | 99.58 Mn | 99.45 Mn | - | -13.15 Mn |
| 7 | Gores Holdings X | 95.80 Mn | 95.37 Mn | - | -31.02 Mn |
| 8 | Archimedes Tech SPAC Partners | 89.88 Mn | 89.88 Mn | - | -6.70 Mn |
| 9 | Cohen Circle Acquisition | 80.05 Mn | 80.05 Mn | - | -9.24 Mn |
| 10 | Drugs Made In America Acquisition | 1.46 Mn | 1.46 Mn | - | -7.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | 608,822.00 |
| Jun 30, 2025 | -7.15 Mn |
| Mar 31, 2025 | -7.18 Mn |
| Dec 31, 2024 | -244,845.00 |